AI assistant
Xilio Therapeutics, Inc. — Director's Dealing 2021
Oct 26, 2021
34726_dirs_2021-10-26_475bf83b-d436-4bfa-b16e-bfc47c7b807d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Xilio Therapeutics, Inc. (XLO)
CIK: 0001840233
Period of Report: 2021-10-26
Reporting Person: Clancy Paul J (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-10-26 | Stock Option (right to buy) | $5.51 | A | 44033 | Acquired | 2030-07-22 | Common Stock (44033) | Direct |
| 2021-10-26 | Stock Option (right to buy) | $5.89 | A | 65528 | Acquired | 2021-03-10 | Common Stock (65528) | Direct |
Footnotes
F1: On July 23, 2020, the reporting person was granted an option to purchase 44,033 shares of common stock of the Company, the vesting of which was contingent upon the closing of the Company's initial public offering ("IPO"). The Company's IPO closed as of October 26, 2021. On October 26, 2021, 13,760 shares underlying the award vested and the remainder will vest in equal monthly installments until July 16, 2024.
F2: On March 11, 2021, the reporting person was granted an option to purchase 65,528 shares of common stock of the Company, the vesting of which was contingent upon the closing of the Company's IPO. The Company's IPO closed as of October 26, 2021. On October 26, 2021, 20,477 shares underlying the option vested and the remainder will vest in equal monthly installments until July 16, 2024.